Piramal Pharma Limited
Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments(1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC).Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and grew through a series of Mergers & Acquisitionsand various organic…
What Piramal files
- Others47
- Investor Meet43
- Important30
- Updates25
- Board Meeting11
- PPTs8
Piramal Pharma kicked off FY27 strongly, reporting consolidated revenue of ₹2,270 Cr, up 17% YoY. EBITDA surged 72% to ₹285 Cr, with margins expanding 400 bps to 12.5%, reflecting improved operations. Net loss improved by 15% to ₹69 Cr. All three segments showed robust growth: CDMO revenue grew 19% to...
Piramal Pharma saw a 3% YoY revenue dip to ₹8,869 Cr in FY26, though Q4 revenues stabilized. CDMO segment revenue declined 10% to ₹4,915 Cr, while Complex Hospital Generics (CHG) grew 3% to ₹2,703 Cr. Consumer Healthcare (PCH) was a bright spot, jumping 17% to ₹1,274 Cr. FY26 EBITDA fell...
Piramal Pharma reported a mixed bag for the quarter and nine months ending December 2025. **Business Performance:** Q3 FY26 revenue dipped 3% YoY to ₹2,140 Cr, with EBITDA falling 32% to ₹239 Cr, reflecting similar nine-month trends. The Contract Development and Manufacturing Organization (CDMO) segment saw a 9% revenue decline...
Piramal Pharma's H1 FY26 saw revenue from operations drop 5% YoY to ₹3,977 Cr, with Q2 revenue at ₹2,044 Cr (down 9% YoY). EBITDA fell 38% for H1 to ₹389 Cr and 44% for Q2 to ₹224 Cr, resulting in a net loss of ₹181 Cr for H1 and ₹99...
**1. Financial Highlights:** Piramal Pharma's Q1FY26 revenue was ₹1,934 Cr, down 1% YoY; excluding a large CDMO destocking, growth was early double-digits. EBITDA hit ₹165 Cr (down 26% YoY, 9% margin). PAT improved 8% to (₹82) Cr. Net-Debt to EBITDA is 2.6x. PPL targets US$2Bn+ revenue and 25% EBITDA margin...